Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Imfinzi (durvalumab)
Pharma
AstraZeneca says Imfinzi keeps stomach cancer from coming back
Imfinzi is the first immunotherapy to significantly improve event-free survival in a phase 3 trial in resectable early-stage stomach cancer.
Angus Liu
Mar 7, 2025 9:48am
BMS's Opdivo scores overall survival triumph in NSCLC trial
Feb 19, 2025 10:06am
AstraZeneca logs China sales decline in Q4 amid probes
Feb 6, 2025 10:31am
FDA signs off on AZ's Imfinzi to treat limited-stage SCLC
Dec 5, 2024 10:58am
AZ's perioperative Imfinzi extends life in bladder cancer type
Sep 15, 2024 10:30am
Amid concerns, FDA approves AZ's Imfinizi in perioperative NSCLC
Aug 16, 2024 10:51am
